How long should a non‑vitamin K antagonist oral anticoagulant (NOAC) be withheld before an oesophagogastroduodenoscopy (OGDS) in a patient with normal renal function and low bleeding risk?

NOAC Withholding Before OGDS

For a patient with normal renal function undergoing OGDS (a low bleeding risk procedure), withhold NOACs for 24 hours before the procedure 1, 2.

Risk Classification

OGDS (oesophagogastroduodenoscopy) without biopsy or therapeutic intervention is classified as a low bleeding risk procedure 1. Diagnostic endoscopy with biopsy also falls into this category 2.

Specific Timing Recommendations

For Patients with Normal Renal Function (CrCl ≥80 mL/min):

• Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban): Last dose ≥24 hours before procedure 1
• Dabigatran: Last dose ≥24 hours before procedure 1

This means skip 1-2 doses depending on whether the NOAC is dosed once or twice daily 1.

For Patients with Impaired Renal Function:

If renal function is reduced (CrCl 50-79 mL/min), consider extending the interruption:

• Dabigatran: ≥36 hours (skip 4 doses) 1
• Factor Xa inhibitors: ≥24 hours remains adequate 1

For CrCl 30-49 mL/min:

• Dabigatran: ≥48 hours 1
• Factor Xa inhibitors: ≥24 hours 1

Important Caveats

No bridging anticoagulation is needed - the predictable pharmacokinetics of NOACs allow safe short-term cessation without heparin bridging 1. Bridging actually increases bleeding risk without reducing thrombotic events 1.

Concomitant medications matter: If the patient takes dronedarone, amiodarone, or verapamil with their NOAC, consider adding an extra 24 hours of interruption, especially if thromboembolic risk is not very high 1.

For diagnostic OGDS specifically: The 2021 BSG/ESGE update 3 and the PAUSE trial support that the morning dose can be omitted on the day of a low-risk procedure, though stopping 24 hours prior (1 day before) is the standard recommendation for consistency.

Resumption of Therapy

Resume NOACs ≥24 hours after the procedure for low bleeding risk interventions 1. This ensures adequate hemostasis before restarting anticoagulation.

Algorithm Summary

1. Confirm normal renal function (CrCl ≥80 mL/min)
2. Last NOAC dose: 24 hours before OGDS (the evening before if morning procedure)
3. No bridging required
4. Resume NOAC: 24 hours after procedure once hemostasis confirmed

This approach is supported by the 2018 European Heart Rhythm Association guidelines 1, the 2016 and 2021 BSG/ESGE guidelines 2, 3, and validated by the PAUSE trial data 3.